Recombinant Human Granulocyte/Macrophage Colonystimulating Factor（rhGM-CSF）
- Generic Name
- Recombinant Human Granulocyte/Macrophage Colonystimulating Factor（rhGM-CSF）
- Indication
用于：1.恶性肿瘤、白血病化、放疗引起的白血病减少及其并发的感染；
2.造血干/祖细胞移植后髓系造血功能受抑及延迟植活与移植排斥；
3.与rhG-CSF等造血生长因子联合或单独应用于外周血造血干/祖细胞移植前的干/祖细胞动员；
4.再生障碍性贫血等骨髓衰竭性疾患及各种严重感染并发的中性粒细胞减少；
5.也可用于艾滋病本身、或因药物治疗所致的中性粒细胞减少。
A Study of Abemaciclib (LY2835219) in Combination With Other Anti-Cancer Treatments in Children and Young Adult Participants With Solid Tumors, Including Neuroblastoma
- Conditions
- Relapsed Solid TumorRefractory Solid Tumor
- Interventions
- First Posted Date
- 2020-01-23
- Last Posted Date
- 2024-06-21
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 117
- Registration Number
- NCT04238819
- Locations
- 🇦🇺
Perth Children's Hospital, Perth, Western Australia, Australia
🇯🇵National Cancer Center Hospital, Chuo Ku, Tokyo, Japan
🇧🇪UZ Gent, Gent, Oost-Vlaanderen, Belgium
Galinpepimut-S Versus Investigator's Choice of Best Available Therapy for Maintenance in AML CR2/CRp2
- Conditions
- Acute Myeloid Leukemia
- Interventions
- Other: MontanideOther: Observation
- First Posted Date
- 2020-01-18
- Last Posted Date
- 2025-05-22
- Lead Sponsor
- Sellas Life Sciences Group
- Target Recruit Count
- 128
- Registration Number
- NCT04229979
- Locations
- 🇺🇸
Mayo Clinic Jacksonville Florida, Jacksonville, Florida, United States
🇫🇷CHU de Caen, Caen, France
🇬🇷General Hospital of Athens "Evaggelismos", Athens, Greece
SBRT in Combination With Sintilimab and GM-CSF for the Treatment of Advanced NSCLC
- First Posted Date
- 2019-09-26
- Last Posted Date
- 2019-09-26
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 63
- Registration Number
- NCT04106180
- Locations
- 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, China
The Effect of the GM-CSF Gel on the Endometrial Thickness in Infertile Women With Thin Endometrium
- First Posted Date
- 2019-09-24
- Last Posted Date
- 2019-09-24
- Lead Sponsor
- Sir Run Run Shaw Hospital
- Target Recruit Count
- 96
- Registration Number
- NCT04100655
- Locations
- 🇨🇳
Sir Run Run Shaw Hospital, Hangzhou, Zhejiang, China
GM-CSF for Reversal of immunopAralysis in pediatriC sEpsis-induced MODS Study
- First Posted Date
- 2018-12-10
- Last Posted Date
- 2023-02-08
- Lead Sponsor
- Nationwide Children's Hospital
- Target Recruit Count
- 120
- Registration Number
- NCT03769844
- Locations
- 🇺🇸
Children's National Medical Center, Washington, District of Columbia, United States
🇺🇸Children's Hospital of Michigan, Detroit, Michigan, United States
🇺🇸Nationwide Children's Hospital, Columbus, Ohio, United States
Galinpepimut-S in Combination With Pembrolizumab in Patients With Selected Advanced Cancers
- Conditions
- Acute Myelogenous LeukemiaOvarian CancerColorectal CancerTriple-negative Breast CancerSmall-cell Lung Cancer
- Interventions
- First Posted Date
- 2018-12-03
- Last Posted Date
- 2024-11-19
- Lead Sponsor
- Sellas Life Sciences Group
- Target Recruit Count
- 26
- Registration Number
- NCT03761914
- Locations
- 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States
🇺🇸St. Joseph Heritage Healthcare, Santa Rosa, California, United States
🇺🇸Innovative Clinical Research Institute (ICRI), Whittier, California, United States
Autologous Stem Cell Transplantation in Patients with Systemic Sclerosis
- Conditions
- Diffuse Sclerosis SystemicInterstitial Lung DiseasePulmonary HypertensionSystemic Sclerosis
- Interventions
- Radiation: Total Body IrradiationDrug: Anti Thymocyte Globulin
- First Posted Date
- 2018-08-14
- Last Posted Date
- 2025-03-17
- Lead Sponsor
- Paul Szabolcs
- Target Recruit Count
- 8
- Registration Number
- NCT03630211
- Locations
- 🇺🇸
Children's Hospital of Pittsburgh of UPMC, Pittsburgh, Pennsylvania, United States
🇺🇸University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States
pTVG-HP and Nivolumab in Patients With Non-Metastatic PSA-Recurrent Prostate Cancer
- Conditions
- Prostate Cancer
- Interventions
- First Posted Date
- 2018-07-26
- Last Posted Date
- 2025-05-09
- Lead Sponsor
- University of Wisconsin, Madison
- Target Recruit Count
- 19
- Registration Number
- NCT03600350
- Locations
- 🇺🇸
University of Wisconsin Carbone Cancer Center, Madison, Wisconsin, United States
UV1 Vaccine With Pembrolizumab for Patients With Unresectable or Metastatic Melanoma
- First Posted Date
- 2018-05-29
- Last Posted Date
- 2024-08-22
- Lead Sponsor
- Ultimovacs ASA
- Target Recruit Count
- 30
- Registration Number
- NCT03538314
- Locations
- 🇺🇸
John Wayne Cancer Center, Santa Monica, California, United States
🇺🇸St. Luke's University Health Network, Easton, Pennsylvania, United States
🇺🇸University of Iowa Carver College of Medicine, Iowa City, Iowa, United States
Allogeneic Myeloma GM-CSF Vaccine With Lenalidomide in Multiple Myeloma Patients in Complete or Near Complete Remission
- Conditions
- Multiple Myeloma
- Interventions
- Other: Placebo Prevnar13Other: Placebo GM-CSF Vaccine
- First Posted Date
- 2017-12-18
- Last Posted Date
- 2024-12-13
- Target Recruit Count
- 54
- Registration Number
- NCT03376477
- Locations
- 🇺🇸
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.